iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.900
-0.030 (-1.55%)
May 29, 2026, 4:00 PM EDT - Market closed
iBio, Inc. Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, iBio, Inc. stock has a consensus rating of "Strong Buy" and an average price target of $5.53. The average 1-year stock price forecast is 191.05% higher than the current stock price, while the lowest is $4.20 (+121.05%) and the highest is $7.00 (+268.42%).
Price Target: $5.53 (+191.05%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for iBio, Inc. stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +163.16% | May 16, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +215.79% | May 15, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $6 | Buy | Maintains | $6 | +215.79% | May 14, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +163.16% | May 14, 2026 |
| JonesTrading | JonesTrading | Buy Initiates $7 | Buy | Initiates | $7 | +268.42% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
183.60K
from 400.00K
Decreased by -54.10%
Revenue Next Year
122.40K
from 183.60K
Decreased by -33.33%
EPS This Year
-0.32
from -1.75
EPS Next Year
-0.30
from -0.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 525,000 | 525,000 | ||||||
| Avg | 183,600 | 122,400 | ||||||
| Low | 98,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.3% | 185.9% | ||||||
| Avg | -54.1% | -33.3% | ||||||
| Low | -75.5% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.29 | -0.20 | |||
| Avg | -0.32 | -0.30 | |||
| Low | -0.34 | -0.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.